Printer Friendly

ICN PHARMACEUTICALS NOT AWARE OF REASON FOR STOCK ACTIVITY

     ICN PHARMACEUTICALS NOT AWARE OF REASON FOR STOCK ACTIVITY
    COSTA MESA, Calif., Nov. 8 /PRNewswire/ -- ICN Pharmaceuticals Inc. (NYSE: ICN) today announced that it was not aware of any reason for the recent activity in the company's stock other than the most recent public announcements previously made by the company.
    The company announced the favorable resolution of the Justice Department investigation and a Securities and Exchange Commission (SEC) investigation in June and October, respectively.  The company's most recent announcement was the approval to market the company's anti-viral drug Virazole in Belgium, in aerosolized form for the treatment of influenza A and B infections in infants and children. The company also announced its third quarter and nine months earnings and that of its subsidiaries, including SPI Pharmaceuticals Inc. (AMEX: SPI), ICN Biomedicals (AMEX: BIM), and Viratek Inc. (NASDAQ: VIRA) during the month of October.  The company is listed on the New York Stock Exchange.
    -0-                      11/8/91
    /CONTACT:  John Giordani of ICN Pharmaceuticals, 714-545-0100/
    (ICN SPI BIM VIRA) CO:  ICN Pharmaceuticals ST:  California IN:  MTC SU: SE-EH -- LA008 -- 2473 11/08/91 08:35 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 8, 1991
Words:185
Previous Article:CARTER HAWLEY HALE REPORTS SEPTEMBER RESULTS
Next Article:RANGER OIL LIMITED ANNOUNCES RESULTS FOR THE NINE MONTHS ENDED SEPTEMBER 30 1991
Topics:


Related Articles
ICN BIOMEDICALS ISSUES $62 MILLION IN PREFERRED STOCK
COMMON STOCKS OF ICN PHARMACEUTICALS, THREE OPERATING UNITS, TOP MAJOR STOCK MARKET INDICES IN 1993
/C O R R E C T I O N -- ICN PHARMACEUTICALS/
ICN PHARMACEUTICALS ISSUES STATEMENT ON RECENT MARKET ACTIVITY
ICN WILL PAY THIRD AND FOURTH QUARTER DIVIDENDS IN DECEMBER
STATEMENT ON STOCK ACTIVITY
ICN Pharmaceuticals Issues $50 Million in Convertible Preferred Stock to Finance Major Expansion Program
ICN Pharmaceuticals Completes $275 Million Note Offering
ICN Announces Proposed $250 Million Convertible Subordinated Notes Offering.
ICN Announces $400 Million Convertible Subordinated Notes Offering.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters